{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:25:33Z","timestamp":1780964733122,"version":"3.54.1"},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T00:00:00Z","timestamp":1470960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,11]]},"abstract":"\n Aims<\/jats:title>\n To compare, in a double\u2010blind, randomized, multi\u2010national study, 52\u2010 or 78\u2010week treatment with basal insulin peglispro or insulin glargine, added to pre\u2010study oral antihyperglycaemic medications, in insulin\u2010na\u00efve adults with type 2 diabetes.<\/jats:p>\n <\/jats:sec>\n \n Material and methods<\/jats:title>\n \n The primary outcome was non\u2010inferiority of peglispro to glargine with regard to glycated haemoglobin (\n HbA1c<\/jats:styled-content>\n ) reduction (margin\u2009=\u20090.4%). Six gated secondary objectives with statistical multiplicity adjustments focused on other measures of glycaemic control and safety. Liver fat content was measured using\n MRI<\/jats:styled-content>\n , in a subset of patients.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Peglispro was non\u2010inferior to glargine in\n HbA1c<\/jats:styled-content>\n reduction [least\u2010squares (\n LS<\/jats:styled-content>\n ) mean difference: \u22120.29%, 95% confidence interval (\n CI<\/jats:styled-content>\n ) \u22120.40, \u22120.19], and had a lower nocturnal hypoglycaemia rate [relative rate 0.74 (95%\n CI<\/jats:styled-content>\n 0.60, 0.91); p\u2009=\u2009.005), more patients achieving\n HbA1c<\/jats:styled-content>\n <7.0% without nocturnal hypoglycaemia [odds ratio (\n OR<\/jats:styled-content>\n ) 2.15 (95%\n CI<\/jats:styled-content>\n 1.60, 2.89); p\u2009<\u2009.001], greater\n HbA1c<\/jats:styled-content>\n reduction (p\u2009<\u2009.001), and more patients achieving\n HbA1c<\/jats:styled-content>\n <7.0% [\n OR<\/jats:styled-content>\n 1.97 (95%\n CI<\/jats:styled-content>\n 1.57, 2.47); p\u2009<\u2009.001]. Total hypoglycaemia rate and fasting serum glucose did not achieve statistical superiority. At 52\u2009weeks, peglispro\u2010treated patients had higher triglyceride (1.9 vs 1.7 mmol\/L). alanine transaminase (34 vs 27\u2009\n IU<\/jats:styled-content>\n \/\n L<\/jats:styled-content>\n ), and aspartate transaminase levels (27 vs 24\n IU<\/jats:styled-content>\n \/\n L<\/jats:styled-content>\n ).\n LS<\/jats:styled-content>\n mean liver fat content was unchanged with peglispro at 52\u2009weeks but decreased 3.1% with glargine [difference: 2.6% (0.9, 4.2); p\u2009=\u2009.002]. More peglispro\u2010treated patients experienced adverse injection site reactions (3.5% vs 0.6%, p\u2009<\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Compared with glargine at 52\u2009weeks, peglispro resulted in a statistically superior reduction in\n HbA1c<\/jats:styled-content>\n , more patients achieving\n HbA1c<\/jats:styled-content>\n targets, less nocturnal hypoglycaemia, no improvement in total hypoglycaemia, higher triglyceride levels, higher aminotransferase levels, and more injection site reactions.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12712","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T04:29:16Z","timestamp":1467088156000},"page":"1055-1064","source":"Crossref","is-referenced-by-count":45,"title":["Basal insulin peglispro versus insulin glargine in insulin\u2010na\u00efve type 2 diabetes:\n IMAGINE<\/scp>\n 2 randomized trial"],"prefix":"10.1111","volume":"18","author":[{"given":"M. J.","family":"Davies","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Diabetes Research Centre University of Leicester Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Russell\u2010Jones","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Royal Surrey County Hospital Guildford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010L.","family":"Selam","sequence":"additional","affiliation":[{"name":"Diabetes Research Center Tustin California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"Bailey","sequence":"additional","affiliation":[{"name":"AMCR Institute Escondido California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Ker\u00e9nyi","sequence":"additional","affiliation":[{"name":"Csepel Health Service Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Luo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bue\u2010Valleskey","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Iv\u00e1nyi","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Hartman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Jacober","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the IMAGINE 2 Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2743"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.9-4-353"},{"key":"e_1_2_6_5_1","first-page":"CD005613","article-title":"Long\u2010acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus","volume":"18","author":"Horvath K","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02517.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2915"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2469"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12117"},{"key":"e_1_2_6_10_1","first-page":"S23","article-title":"Leveraging hydrodynamic size to develop a novel basal insulin","volume":"55","author":"Beals JM","year":"2012","journal-title":"Diabetologia"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12222"},{"key":"e_1_2_6_12_1","first-page":"LB22","article-title":"Basal Insulin peglispro (BIL) demonstrates hepato\u2010preferential action vs. insulin Glargine (GL) in patients with type 1 diabetes mellitus (T1DM)","volume":"64","author":"Mudaliar S","year":"2015","journal-title":"Diabetes"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0210"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0826"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-5926-1-1"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/apha.12076"},{"key":"e_1_2_6_17_1","unstructured":"World Health Organization International Diabetes Federation.Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO\/IDF consultation.2006 WHO Document Production Services Geneva Switzerland 50p."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"e_1_2_6_19_1","unstructured":"US DHHS FDA CDER.Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention.2008:27.http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm071624.pdf. Accessed July 2016"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3307"},{"key":"e_1_2_6_21_1","unstructured":"US DHHS FDA CDER CBER CDRH.Guidance for industry: patient\u2010reported outcome measures: use in medical product development to support labeling claims.2009:28.http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/UCM193282.pdf. Accessed July 2016"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1658"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0332"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1576"},{"key":"e_1_2_6_25_1","unstructured":"US DHHS FDA CDER CBER.Guidance for industry: drug\u2010induced liver injury: premarketing clinical evaluation.2009:8.http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/UCM174090.pdf. Accessed July 2016"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0911-x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1357"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.11.2811"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905479"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(89)90240-0"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.10.1596"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.160192"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1423952112"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02312"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00133.2006"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1531"},{"key":"e_1_2_6_37_1","first-page":"A262","article-title":"Lymphatic absorption of basal insulin peglispro (BIL) in sheep","volume":"64","author":"Knadler MP","year":"2015","journal-title":"Diabetes"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12712","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12712","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:34:26Z","timestamp":1761878066000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,12]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/dom.12712"],"URL":"https:\/\/doi.org\/10.1111\/dom.12712","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,12]]}}}